Published in J Neuroinflammation on September 08, 2010
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation (2012) 3.12
Aquaporin 4 and neuromyelitis optica. Lancet Neurol (2012) 2.58
Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol (2013) 1.79
Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain. Ann Neurol (2012) 1.54
Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. Nat Rev Neurol (2014) 1.53
Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm (2015) 1.49
Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol (2014) 1.38
Retracted Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies. Mult Scler Int (2011) 1.26
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation (2016) 1.20
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation (2016) 1.01
Brain-reactive antibodies and disease. Annu Rev Immunol (2013) 0.94
Modifications of longitudinally extensive transverse myelitis and brainstem lesions in the course of neuromyelitis optica (NMO): a population-based, descriptive study. BMC Neurol (2013) 0.94
The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives. Int J Mol Sci (2016) 0.93
Optic neuritis in neuromyelitis optica. Prog Retin Eye Res (2013) 0.90
Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases? EPMA J (2013) 0.89
The cerebrospinal fluid immunoglobulin transcriptome and proteome in neuromyelitis optica reveals central nervous system-specific B cell populations. J Neuroinflammation (2015) 0.87
Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study. J Neuroinflammation (2014) 0.85
Immunopathological patterns from EAE and Theiler's virus infection: Is multiple sclerosis a homogenous 1-stage or heterogenous 2-stage disease? Pathophysiology (2012) 0.85
B lymphocytes in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm (2015) 0.85
Clinical utility of testing AQP4-IgG in CSF: Guidance for physicians. Neurol Neuroimmunol Neuroinflamm (2016) 0.84
Cerebrospinal fluid aquaporin-4-immunoglobulin G disrupts blood brain barrier. Ann Clin Transl Neurol (2015) 0.84
The growing spectrum of antibody-associated inflammatory brain diseases in children. Neurol Neuroimmunol Neuroinflamm (2015) 0.84
Neuromyelitis optica spectrum disorders associated with other autoimmune diseases. Rheumatol Int (2014) 0.84
Evaluation of aquaporin-4 antibody assays. Clin Exp Neuroimmunol (2014) 0.84
Aquaporin-4 antibody testing: direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate. J Neuroinflammation (2014) 0.83
Neuromyelitis optica study model based on chronic infusion of autoantibodies in rat cerebrospinal fluid. J Neuroinflammation (2016) 0.81
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome. J Neuroinflammation (2016) 0.80
Characterization of the binding pattern of human aquaporin-4 autoantibodies in patients with neuromyelitis optica spectrum disorders. J Neuroinflammation (2016) 0.79
Clinical Features of Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. Chin Med J (Engl) (2016) 0.79
Aquaporin-4 antibody isoform binding specificities do not explain clinical variations in NMO. Neurol Neuroimmunol Neuroinflamm (2015) 0.78
Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase. Clin Exp Immunol (2015) 0.78
Evaluation of clinical interest of anti-aquaporin-4 autoantibody followup in neuromyelitis optica. Clin Dev Immunol (2013) 0.77
Analysis of antibodies to surface epitopes of contactin-2 in multiple sclerosis. J Neuroimmunol (2012) 0.77
Interferon-β-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab. BMC Neurol (2014) 0.76
Features of anti-aquaporin 4 antibody-seropositive Chinese patients with neuromyelitis optica spectrum optic neuritis. J Neurol (2015) 0.76
Fulminant neuromyelitis optica in a Finnish woman - a case report. Clin Case Rep (2016) 0.75
Enhancing Brain Lesions during Acute Optic Neuritis and/or Longitudinally Extensive Transverse Myelitis May Portend a Higher Relapse Rate in Neuromyelitis Optica Spectrum Disorders. AJNR Am J Neuroradiol (2017) 0.75
KIR4.1 Antibodies as Biomarkers in Multiple Sclerosis. Front Neurol (2014) 0.75
The Neuroepithelium Disruption Could Generate Autoantibodies against AQP4 and Cause Neuromyelitis Optica and Hydrocephalus. Int Sch Res Notices (2014) 0.75
Pathogenic implications of cerebrospinal fluid barrier pathology in neuromyelitis optica. Acta Neuropathol (2017) 0.75
Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm (2017) 0.75
Finding NMO: The Evolving Diagnostic Criteria of Neuromyelitis Optica. J Neuroophthalmol (2016) 0.75
Hypersensitivity Responses in the Central Nervous System. Front Immunol (2015) 0.75
The Role of Brain-Reactive Autoantibodies in Brain Pathology and Cognitive Impairment. Front Immunol (2017) 0.75
Neuromyelitis optica presenting as intractable vomiting and hyperCKaemia. J Neurol (2015) 0.75
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol (2001) 24.36
Revised diagnostic criteria for neuromyelitis optica. Neurology (2006) 17.57
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet (2004) 13.18
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med (2005) 10.39
The clinical course of neuromyelitis optica (Devic's syndrome). Neurology (1999) 8.03
Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol (2009) 4.88
Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain (2007) 4.82
Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain (2010) 3.95
Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol (2009) 3.91
Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology (2007) 3.83
AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol (2010) 3.28
NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology (2008) 3.21
Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. J Neurol Sci (2001) 3.11
Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain (2008) 2.96
Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol (2006) 2.80
Quantification of virus-specific antibodies in cerebrospinal fluid and serum: sensitive and specific detection of antibody synthesis in brain. Clin Chem (1991) 2.52
Flow rate of cerebrospinal fluid (CSF)--a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases. J Neurol Sci (1994) 2.51
Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol (2008) 2.48
Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol (2008) 2.40
Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med (2008) 2.26
Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry (1996) 2.02
Serum proteins bypass the blood-brain fluid barriers for extracellular entry to the central nervous system. Exp Neurol (1993) 1.95
Interrelationships of the pia mater and the perivascular (Virchow-Robin) spaces in the human cerebrum. J Anat (1990) 1.81
The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult Scler (1998) 1.80
NMO-IgG in the diagnosis of neuromyelitis optica. Neurology (2007) 1.77
Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. J Neurol Sci (2010) 1.75
Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med (2007) 1.61
Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J Immunol (2008) 1.58
Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay. J Neuroimmunol (2008) 1.51
Macromolecular permeability across the blood-nerve and blood-brain barriers. Proc Natl Acad Sci U S A (1994) 1.50
Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells. Biochem Biophys Res Commun (2010) 1.40
Altered blood-brain barrier integrity in adult aquaporin-4 knockout mice. Neuroreport (2008) 1.40
NMO-IgG detected in CSF in seronegative neuromyelitis optica. Neurology (2009) 1.38
Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica. J Neurol (2004) 1.38
Cerebrospinal fluid--physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases. Mult Scler (1998) 1.33
Immunological and neuropathological significance of the Virchow-Robin space. J Neurol Sci (1990) 1.04
Importance of cerebrospinal fluid examination in differential diagnosis of Devic's neuromyelitis optica by multiple sclerosis. Neurol Sci (2003) 0.86
Cerebrospinal fluid findings in Devic's neuromyelitis optica. Neurol Sci (2004) 0.83
Selective complexing of acetylcholinesterase in brain by intravenously administered monoclonal antibody. J Neurochem (1990) 0.81
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
No cerebrocervical venous congestion in patients with multiple sclerosis. Ann Neurol (2010) 4.31
Photoreceptor layer thinning in idiopathic Parkinson's disease. Mov Disord (2014) 3.36
AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol (2010) 3.28
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation (2012) 3.12
N-methyl-D-aspartate receptor antibodies in herpes simplex encephalitis. Ann Neurol (2012) 2.91
Laparoscopic sigmoid resection for diverticulitis decreases major morbidity rates: a randomized control trial: short-term results of the Sigma Trial. Ann Surg (2009) 2.89
Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med (2007) 2.88
Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol (2008) 2.40
Seroprevalence of autoantibodies against brain antigens in health and disease. Ann Neurol (2014) 2.36
Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation (2011) 2.35
Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur J Immunol (2005) 2.28
Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls. PLoS One (2009) 2.14
Toward the blood-borne miRNome of human diseases. Nat Methods (2011) 2.14
Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol (2012) 2.12
Administration of fibrinogen concentrate in exsanguinating trauma patients is associated with improved survival at 6 hours but not at discharge. J Trauma Acute Care Surg (2013) 2.06
A novel human polyomavirus closely related to the african green monkey-derived lymphotropic polyomavirus. J Virol (2011) 2.03
L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology (2013) 2.02
A blood based 12-miRNA signature of Alzheimer disease patients. Genome Biol (2013) 1.99
The impact of sleep deprivation on product quality and procedure effectiveness in a laparoscopic physical simulator: a randomized controlled trial. Am J Surg (2005) 1.95
MR-elastography reveals degradation of tissue integrity in multiple sclerosis. Neuroimage (2009) 1.83
Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol (2013) 1.79
Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease. Mult Scler (2012) 1.77
Prevalence of newly generated naive regulatory T cells (Treg) is critical for Treg suppressive function and determines Treg dysfunction in multiple sclerosis. J Immunol (2007) 1.74
Postinfectious neurologic syndromes: a prospective cohort study. Neurology (2013) 1.73
Impairment of contrast visual acuity as a functional correlate of retinal nerve fibre layer thinning and total macular volume reduction in multiple sclerosis. Br J Ophthalmol (2011) 1.73
Determinants of recurrence after sigmoid resection for uncomplicated diverticulitis. Dis Colon Rectum (2003) 1.70
Complication rates after Hartmann's reversal: open vs. laparoscopic approach. Dis Colon Rectum (2008) 1.69
Characteristics of Susac syndrome: a review of all reported cases. Nat Rev Neurol (2013) 1.69
Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica. PLoS One (2010) 1.68
Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy. Clin Chim Acta (2013) 1.68
Herpes simplex virus encephalitis despite normal cell count in the cerebrospinal fluid. Crit Care Med (2012) 1.67
Use of a type I/III bilayer collagen membrane decreases reoperation rates for symptomatic hypertrophy after autologous chondrocyte implantation. Am J Sports Med (2009) 1.67
Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis. Neurology (2012) 1.67
Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature. Brain Pathol (2013) 1.63
Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells. Arch Neurol (2008) 1.62
Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med (2007) 1.61
In contrast to effector T cells, CD4+CD25+FoxP3+ regulatory T cells are highly susceptible to CD95 ligand- but not to TCR-mediated cell death. J Immunol (2005) 1.58
Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia (2007) 1.56
Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment. Neurology (2009) 1.53
T-cell homeostasis in pediatric multiple sclerosis: old cells in young patients. Neurology (2013) 1.51
Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. Neurology (2014) 1.45
Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci (2010) 1.45
Functional and structural brain changes in anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol (2013) 1.42
Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma. BMC Cancer (2005) 1.42
Brain viscoelasticity alteration in chronic-progressive multiple sclerosis. PLoS One (2012) 1.41
The N3 potential compared to sound and galvanic vestibular evoked myogenic potential in healthy subjects and in multiple sclerosis patients. J Vestib Res (2007) 1.41
No rectopexy versus rectopexy following rectal mobilization for full-thickness rectal prolapse: a randomized controlled trial. Dis Colon Rectum (2011) 1.41
Specific immunoadsorption of pathogenic autoantibodies in pemphigus requires the entire ectodomains of desmogleins. Exp Dermatol (2014) 1.40
Detection of occult liver metastases in colorectal cancer by measurement of biliary carcinoembryonic antigen concentration: a prospective study. J Surg Oncol (2004) 1.39
Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica. J Neurol (2004) 1.38
Perivascular spaces--MRI marker of inflammatory activity in the brain? Brain (2008) 1.33
Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis. Ann Neurol (2009) 1.32
Spinal cord lesions in patients with neuromyelitis optica: a retrospective long-term MRI follow-up study. Eur Radiol (2009) 1.31
Patterns of retinal nerve fiber layer loss in multiple sclerosis patients with or without optic neuritis and glaucoma patients. Clin Neurol Neurosurg (2010) 1.30
Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome. Mult Scler (2013) 1.30
Thymic export function and T cell homeostasis in patients with relapsing remitting multiple sclerosis. J Immunol (2003) 1.29
The current status of robotic pelvic surgery: results of a multinational interdisciplinary consensus conference. Surg Endosc (2008) 1.27
Progressive encephalomyelitis with rigidity and myoclonus: a new variant with DPPX antibodies. Neurology (2014) 1.26
Retracted Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies. Mult Scler Int (2011) 1.26
No evidence for XMRV in German CFS and MS patients with fatigue despite the ability of the virus to infect human blood cells in vitro. PLoS One (2010) 1.25
The history of neuromyelitis optica. J Neuroinflammation (2013) 1.25
Retinal damage in multiple sclerosis disease subtypes measured by high-resolution optical coherence tomography. Mult Scler Int (2012) 1.24
Optic neuritis interferes with optical coherence tomography and magnetic resonance imaging correlations. Mult Scler (2012) 1.23
Multicenter case-control study on restless legs syndrome in multiple sclerosis: the REMS study. Sleep (2008) 1.22
What went wrong? The flawed concept of cerebrospinal venous insufficiency. J Cereb Blood Flow Metab (2013) 1.19
Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Mult Scler (2011) 1.19
Human endogenous retrovirus (HERV)-W ENV and GAG proteins: physiological expression in human brain and pathophysiological modulation in multiple sclerosis lesions. J Neurovirol (2005) 1.19
Reduced NAA-levels in the NAWM of patients with MS is a feature of progression. A study with quantitative magnetic resonance spectroscopy at 3 Tesla. PLoS One (2010) 1.18
Lesion morphology at 7 Tesla MRI differentiates Susac syndrome from multiple sclerosis. Mult Scler (2012) 1.18
Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis. PLoS One (2013) 1.18
Comprehensive analysis of microRNA profiles in multiple sclerosis including next-generation sequencing. Mult Scler (2013) 1.16